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Structural Biology Group, European Synchrotron Radiation Facility, Grenoble, France
Neurons are extremely energy demanding cells and highly dependent on the
mitochondrial oxidative phosphorylation (OXPHOS) system. Mitochondria generate the
energetic potential via the respiratory complexes I to IV, which constitute the electron
transport chain (ETC), together with complex V. These redox reactions release energy in
the form of ATP and also generate reactive oxygen species (ROS) that are involved in cell
signaling but can eventually lead to oxidative stress. Complex I (CI or NADH:ubiquinone
oxidoreductase) is the largest ETC enzyme, containing 44 subunits and the main
contributor to ROS production. In recent years, the structure of the CI has become
available and has provided new insights into CI assembly. A number of chaperones have
been identified in the assembly and stability of the mature holo-CI, although they are
not part of its final structure. Interestingly, CI dysfunction is the most common OXPHOS
disorder in humans and defects in the CI assembly process are often observed. However,
the dynamics of the events leading to CI biogenesis remain elusive, which precludes our
understanding of how ETC malfunctioning affects neuronal integrity. Here, we review
the current knowledge of the structural features of CI and its assembly factors and the
potential role of CI misassembly in human disorders such as Complex I Deficiencies or
Alzheimer’s and Parkinson’s diseases.
Keywords: complex I, MCIA, assembly factors, mitochondrial dysfunction, neurodegeneration, Alzheimer’s
disease, Parkinson’s disease
INTRODUCTION
The major mechanisms mediating neuronal activity are all initially powered by the oxidative
phosphorylation system (OXPHOS) in mitochondria, the so-called “powerhouse” of the cell
(Hall et al., 2012). They generate energetic potential through the electron transport chain
(ETC) which includes complex I (CI or NADH:ubiquinone oxidoreductase), complex II
(CII or succinate:ubiquinone oxidoreductase), complex III (CIII or ubiquinol:cytochrome-c
oxidoreductase), and complex IV (CIV or cytochrome-c oxidase). Together with complex V
Abbreviations: OXPHOS, oxidative phosphorylation system; CI, complex I; ETC, electron transfer chain; ROS, reactive
oxygen species; mtDNA, mitochondrial DNA; FAD, flavine adenine nucleotide; MTS, mitochondrial targeting sequence;
MCIA, mitochondrial CI assembly; ND, neurodegenerative diseases; AD, Alzheimer’s disease; PD, Parkinson’s disease;
CID, complex I deficiencies; LS, Leigh syndrome; MELAS, mitochondrial encephalomyopathy, lactic acidosis and stroke-
like episodes syndrome; NARP, neuropathy, ataxia, and retinitis pigmentosa syndrome; tg mice, transgenic mice; NFT,
neurofibrillary tangles; Aβ, amyloid-β peptide; APP, amyloid precursor protein.
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(CV or FOF1-ATP-synthase) they form what is usually called the
OXPHOS system. Biogenesis of a functional OXPHOS system
requires a large set (>92) of mitochondrial- and nuclear-encoded
proteins (Koopman et al., 2013). Despite the critical importance
of the CI in energy production, many aspects of its structure,
assembly and activity are still poorly understood. Here, we
provide an overview of the current knowledge of CI structure
and the factors involved in its assembly, with an emphasis on the
Mitochondrial Complex I Assembly (MCIA) complex. We then
examine the supporting evidence that correlates CI dysfunction
and misassembly with neurodegeneration, in particular Complex
I Deficiencies, Alzheimer’s and Parkinson’s diseases. Overall, this
review attempts to explore recent advances into the molecular
mechanisms of CI assembly based on structural and clinical
studies in order to provide a better understanding of its
underlying mechanisms in neurodegenerative disorders.
MITOCHONDRIAL ENERGY PRODUCTION
IN NEURONS: THE CRITICAL ROLE OF
THE OXIDATIVE PHOSPHORYLATION
SYSTEM
As a first step in oxidative phosphorylation, fuel molecules
(such as monosaccharides and fatty acids) are transferred to
nicotinamide (NAD) and flavine adenine (FAD) nucleotides
through glycolysis, Krebs cycle and β-oxidation and are then
oxidized through the ETC. CI, CIII, and CIV generate proton
force in the intermembrane space and their actions are facilitated
by CII and electron transfer cofactors (i.e., ubiquinone and
cytochrome-c). Proton translocation back to the mitochondrial
matrix drives CV, which is coupled to ATP synthesis. Most of
the ATP produced by CV is exchanged against cytosolic ADP
through a specific adenine nucleotide carrier to supply the rest
of the cell with energy and to maintain the ADP phosphorylation
capacity of mitochondria (Lasserre et al., 2015).
Many inner membrane transporters are also driven by
the electrochemical proton gradient, which is required for
the maintenance of mitochondrial integrity and essential
functions like apoptosis, innate immunity, redox control, calcium
homeostasis, and several biosynthetic processes (Koopman et al.,
2013).
The redox reactions involved in energy production generate
reactive oxygen species (ROS), which have important roles in
cell signaling and homeostasis. However, high levels of ROS
can also lead to oxidative stress. ROS levels are particularly
critical in the central nervous system (CNS) since neurons are
extremely energy demanding but have limited glycolysis, making
them highly dependent on an efficient OXPHOS. The ability of
the brain to withstand oxidative stress is limited because of (a)
high content of easily oxidizable substrates; (b) relatively low
levels of antioxidants; (c) the endogenous generation of ROS
via several specific reactions; (d) the elevated content of iron
in specific areas of the human brain, and (e) CNS contains
non-replicating neuronal cells which, once damaged, may be
permanently dysfunctional or committed to apoptosis (Calabrese
and Halpain, 2005; Cao and Fang, 2015; Wakatsuki et al., 2015).
Thus, it is not surprising that mitochondria of synaptic origin can
be highly affected in response to physiological or environmental
alterations, with severe consequences for neuronal function and
survival. Metabolically, there is evidence that both neurons
and astrocytes rely on OXPHOS for ATP generation, whereas
astrocytes also possess energy stores in the form of glycogen
(Hertz et al., 2007; Belanger et al., 2011). Moreover, the ability
of mitochondria to move within the cells is also critical in highly
polarized cells like neurons. Data from rat brain mitochondria
of non-synaptic origin have shown that ETC complex activities
need to be reduced by at least 60% before major changes in ATP
synthesis and oxygen consumption occur. However, in synaptic
mitochondria, titration of various ETC complexes with specific
inhibitors show that decreased CI, III, and IV activities of 25,
80, and 70%, respectively, result in major changes in rates of
oxygen consumption and ATP synthesis (Telford et al., 2009).
This suggests that in mitochondria of synaptic origin, CI activity
has a major control of oxidative phosphorylation, such that when
a relatively low threshold of 25% inhibition is exceeded, energy
metabolism is compromised, and reduction in ATP synthesis
ensues (Telford et al., 2009).
Even though the basic functional principles of most
components of the ETC have been elucidated, the details are still
being hotly debated. We now know that each complex in the
chain functions with a unique mechanism and that there are no
direct analogs with other enzymes (Sazanov, 2015).
MITOCHONDRIAL RESPIRATORY
COMPLEX I: STRUCTURE AND FUNCTION
CI is the largest and first enzyme of the ETC. It is essential for
cellular energy production, providing about 40% of the proton
motive force required for ATP synthesis. It oxidizes NADH
to NAD+ and donates the released electrons to the electron
carrier coenzyme Q10 (CoQ10, also known as ubiquinone),
linking this process to the translocation of four protons
from the mitochondrial matrix to the intermembrane space
(Figure 1; Sazanov, 2014). These electron transfers generate
superoxide (O·−2 ), which is the proximal mitochondrial ROS
(St-Pierre et al., 2002; Kussmaul and Hirst, 2006; Murphy,
2009). Superoxide is normally converted to H2O2 by manganese
superoxide dismutase (MnSOD); the latter can easily diffuse
across the membranes and be quickly reduced to water by
mitochondrial and cytoplasmic peroxiredoxins, catalases, and
glutathione peroxidases (Cox et al., 2010; Li et al., 2013).
Mammalian CI is composed of 44 different subunits, all of
which are integral components of the enzyme (approximately
1MDa). Seven of these subunits (ND1, ND2, ND3, ND4,
ND4L, ND5, and ND6) are encoded by the mitochondrial DNA
(mtDNA) and the rest by the nuclear DNA (Vinothkumar
et al., 2014). The prokaryotic counterpart of CI contains only
the 14 highly conserved core subunits (a total mass of about
550 kDa), which harbor the bioenergetic functions. The extra
counterparts seen in mammalian CI are thus called accessory or
supernumerary subunits (Letts and Sazanov, 2015).
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FIGURE 1 | Schematic overview of the functional complex I modules. In the N-module (colored in green), the oxidation of NADH by a flavin mononucleotide
(FMN) generates the release of two electrons (2e−) that enter into a chain of seven iron–sulfur (Fe-S) clusters (orange spheres). They are transferred from the terminal
Fe-S cluster N2 onto a ubiquinone molecule (Q−10) bound in the Q-module (in gold) which gets reduced (Q10H2). The reduction of ubiquinone induces conformational
changes in the helices of the proton-translocating P-modules (Pp-proximal in violet and Pd-distal in salmon). As a result, a long chain of charged residues passing
through the middle of the membrane connects to four putative pump sites consisting of separate proton input (from matrix) and output (to periplasm) channels. The
reduced FMN cofactor also reacts with molecular oxygen to form reactive oxygen species, highlighted in red. MIM: mitochondrial inner membrane. Representation of
mammalian mitochondrial CI model is based on the bovine heart cryo-EM structure Representation of mammalian mitochondrial CI model is based on the bovine
heart cryo-EM structure (Vinothkumar et al., 2014; PDB 4UQ8).
While the atomic-resolution structures and basic mechanisms
of most respiratory complexes have been previously established,
there are still large gaps in our understanding of the coupled
electron transport and proton pumping in the OXPHOS
complexes, being the CI the least understood (Letts and Sazanov,
2015). Crystal structures have been reported for prokaryotic CIs
(also called NADH dehydrogenase-1) such as from Escherichia
coli (Efremov and Sazanov, 2010, 2011), T. thermophilus
(Baradaran et al., 2013), P. denitrificans (Sedlacek et al., 2014),
and A. aeolicus (Yeh et al., 2000), reviewed in Berrisford
and Sazanov (2009). Structural models are also available for
eukaryotic CI, such as from the obligate aerobic yeast Y. lipolytica
(Zickermann et al., 2015) and the fungus Neurospora crassa
(Janssen et al., 2006). Furthermore, the recent cryo-EM structure
of bovine heart CI has enabled the molecular modeling of the
14 core subunits plus 14 of the supernumerary subunits of the
mammalian enzyme (Vinothkumar et al., 2014). Nevertheless,
higher resolution data are still required for a full assignment
of the rest of the supernumerary subunits to build a complete
mammalian CI structural model (Letts and Sazanov, 2015).
Eukaryotic CI seems to be organized into four functional
modules (Figure 1). It forms an L-shaped arm, composed of
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hydrophilic (matrix-protruding and peripheral) and lipophilic
(inner membrane-embedded) segments (Clason et al., 2010). The
two constituents have independent functions. The peripheral arm
extends into thematrix and is responsible for the electron transfer
reaction while the membrane arm catalyzes proton transport
(Sazanov, 2015). The distal half of the matrix arm forms the
N module that is made up of the central 75, 51, and 24-kDa
subunits and contains the dehydrogenase site, formed by a flavin-
mononucleotide (FMN)moiety and responsible for the oxidation
of NADH to NAD+. The proximal half of the peripheral arm
is the Q module. This reduces ubiquinone and is composed of
the central 49-kDa, 30-kDa, PSST, and TYKY subunits, docking
onto the membrane arm. A chain of eight iron-sulfur clusters
runs over a distance of about 100 Å through the matrix arm
allowing fast electron tunneling (Zickermann et al., 2015) in
a very similar manner to that seen in prokaryotic CI, except
that, owing to rotation of the 51- and 24-kDa subunits, the
mammalian counterpart chains are more distal to the membrane
and more divergent (Vinothkumar et al., 2014). The membrane
arm contains 82 transmembrane helices (TMHs), 64 of them
contributed by central subunits. The mammalian membrane
domain is more strongly curved out of the membrane plane than
the prokaryotic analog, mainly due to a transmembrane helix in
subunit ND6 (Vinothkumar et al., 2014). The proximal pump
module (PP) comprises the central subunits ND1, ND2, ND3,
ND4L, and ND6, whereas the distal pump module (PD) contains
the central subunits ND4 andND5. The interior of themembrane
arm is rich in polar and protonable residues (i.e., residues
that may take up or release protons) constituting a remarkable
hydrophilic central axis across all subunits (Zickermann et al.,
2015).
Taken together, the overall architecture of the CI supports
the idea that proton translocation is driven by long-range
conformational changes. However, the energy-converting
mechanism of CI remains largely unknown (Hirst and Roessler,
2015; Letts and Sazanov, 2015). Furthermore, many important
structural details remain to be elucidated, including, for instance,
the role of several single transmembrane ancillary subunits,
which are proposed to form a scaffold structure holding the giant
complex during its oscillatory movements; or when and how the
different prosthetic groups are incorporated into the complex
(Ghezzi and Zeviani, 2012). Along this line, CI has been long
known to be inhibited by Zn2+, but the site of inhibitory Zn2+
binding remains to be identified (Hirst and Roessler, 2015).
COMPLEX I CONSTRUCTION: THE
CRITICAL ROLE OF ASSEMBLY FACTORS
Specific pathways are required for the assembly of each ETC
complex, including the transfer of nuclear and mtDNA-encoded
ETC subunits into the inner membrane of mitochondria; the
synthesis and incorporation of several prosthetic groups that
form the catalytic redox cores of CI, CII, CIII, and CIV; and the
ultimate formation of functionally active holo-complexes, which
can also organize themselves in respiratory supercomplexes
(Ghezzi and Zeviani, 2012). Additional systems verify the quality
control of protein and non-protein components of the ETC
complexes, contributing to the maintenance of their structural
integrity, functional activity, and turnover. Thus, a highly
regulated, extremely complex process is at work in mitochondria
to control the formation, stability, interactions, function, and
plasticity of the ETC (Ghezzi and Zeviani, 2012).
CI assembly is a complicated multistep process. Previous
studies on mammalian CI biogenesis have used patient cells
containing assembly defects to generate models of CI assembly
(Lazarou et al., 2007). The presence of CI subunits in
mobile (matrix-soluble) and/or immobile (membrane-bound)
subassemblies in vivo indicates that a modular CI assembly
pathway is operational in different mitochondrial compartments
in the living cell (Dieteren et al., 2008). In addition, in
human mitochondria CI is found exclusively as a component
of respiratory supercomplexes, since it requires CIII for stability
(Schagger et al., 2004; Moreno-Lastres et al., 2012). Although
it is not known exactly how each subunit is assembled to form
the mature CI in humans, a model for its assembly has been
developed in recent years (Vogel et al., 2007b; Mckenzie and
Ryan, 2010). Based on this, a stepwise assembly process of CI
would involve pre-assembled modules of the peripheral matrix
and membrane arms (Figure 1; Letts and Sazanov, 2015). Even
if current data on CI assembly accounts for the addition of only
16 of the 30 mammalian mitochondria supernumerary subunits,
they still provide strong clues concerning to which of the core
subunits these supernumerary subunits are binding (Letts and
Sazanov, 2015). Consistent with the highly hydrophobic nature
of the proteins located in the P module, the membrane arm
forms an assembly intermediate, including ND2, ND4, ND4L,
ND5, and ND6 mitochondrial subunits before the progression
into the mature holo-enzyme (Leman et al., 2015). Nevertheless,
previous studies have demonstrated that subassemblies of nuclear
DNA-encoded CI subunits could be formed in the absence
of mtDNA-encoded subunits, suggesting that the presence of
the mitochondrial-encoded subunits is not required for the
formation of the peripheral arm subcomplex (Potluri et al., 2004).
The Q module seems to assemble separately from the N module
and associate with the membrane arm in a late stage intermediate
of roughly 830 kDa. In a last step, the subunits of the tip of CI, i.e.,
subunits of the N module (core catalytic NDUFV1, NDUFV2,
and NDUFS1 subunits and accessory NDUFV3, NDUFS4, 6 and
NDUFA12 subunits) seem to be added to form a functional
holo-enzyme (reviewed in Mckenzie and Ryan, 2010).
The integration of these subunits and insertion of cofactors
into the nascent CI is aided by assembly factors, which tend
to be specific for each complex but bind transiently without
forming part of the final enzyme (Fernandez-Vizarra et al.,
2009; Torraco et al., 2015; Sanchez-Caballero et al., 2016; Wirth
et al., 2016). At least 13 assembly factors have now been
identified and characterized to be involved in CI assembly
(Table 1; Mimaki et al., 2012). They are encoded in the nucleus
and are then delivered to the mitochondria. To ensure proper
delivery, the majority contains a specific N-terminal signal pre-
sequence, also called mitochondrial targeting sequence (MTS)
that is removed after import by the mitochondrial processing
peptidase. Nevertheless, some proteins do not contain a cleavable
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TABLE 1 | CI assembly factors and interacting CI subunits.
Interactors Description CI interacting subunits References
ACAD9 Acyl-CoA dehydrogenase family
member 9, mitochondrial
Core: NDUFS2, NDUFS3, NDUFS7, ND6 Nouws et al., 2010
Accessory: NDUFA13, NDUFS5
ECSIT Evolutionarily conserved signaling
intermediate in Toll pathway,
mitochondrial
Core: NDUFS1, NDUFS2, NDUFS3, NDUFS8, ND1, ND4 Vogel et al., 2007a
Accessory: NDUFA3, NDUFA8, NDUFA13, NDUFB1,
NDUFB5, NDUFB8, NDUFB11, NDUFS5, NDUFC2
FOXRED1 FAD-dependent oxidoreductase
domain-containing protein 1
Accessory: NDUFS5 Formosa et al., 2015
NDUFAF1 Complex I intermediate-associated
protein 30, mitochondrial
Core: NDUFS1, NDUFS3, NDUFS7, ND1 Vogel et al., 2005
Accessory: NDUFA8, NDUFA9, NDUFA12, NDUFA13,
NDUFB6, NDUFB11, NDUFS5
NDUFAF2 NADH dehydrogenase [ubiquinone] 1
alpha subcomplex assembly factor 2
n.d. Ogilvie et al., 2005
NDUFAF3 NADH dehydrogenase [ubiquinone] 1
alpha subcomplex assembly factor 3
Core: NDUFS2, NDUFS3, NDUFS7, ND6 Saada et al., 2009
Accessory: NDUFA8, NDUFA13, NDUFB10, NDUFB11,
NDUFS4, NDUFS5, NDUFS8
NDUFAF4 NADH dehydrogenase [ubiquinone] 1
alpha subcomplex assembly factor 4
Core: NDUFS3, NDUFS7 Saada et al., 2008
Accessory: NDUFA13, NDUFS5
NDUFAF5 NADH dehydrogenase [ubiquinone] 1
alpha subcomplex assembly factor 5
Core: NDUFS3, NDUFS7 Sugiana et al., 2008
Accessory: NDUFA10
NDUFAF6 NADH dehydrogenase [ubiquinone] 1
alpha subcomplex assembly factor 6
n.d. McKenzie et al., 2011
NDUFAF7 NADH dehydrogenase [ubiquinone] 1
alpha subcomplex assembly factor 7
Core: NDUFS7 Carilla-Latorre et al., 2010
Accessory: NDUFA10
NUBPL Iron-sulfur protein NUBPL
(Nucleotide-binding protein-like)
n.d. Sheftel et al., 2009
TIMMDC1 Complex I assembly factor TIMMDC1
(Translocase of inner mitochondrial
membrane domain-containing protein
1), mitochondrial
Core: NDUFS2, NDUFS7, NDUFS8, NDUFV1, ND1, ND2,
ND4
Andrews et al., 2013
Accessory: NDUFA3, NDUFA8, NDUFA9, NDUFA12,
NDUFA13, NDUFB4, NDUFB5, NDUFB6, NDUFB8,
NDUFB9, NDUFB10, NDUFS5, NDUFV3
TMEM126B Complex I assembly factor
TMEM126B (Transmembrane protein
126B), mitochondrial
Accessory: NDUFA13 Heide et al., 2012
Interactions curated by Intact (Orchard, 2014) and Biogrid (Chatraryamontri et al., 2015).
n.d., no data available.
MTS. These include three CI assembly factors: TMEM126B,
FOXRED1, and TIMMDC1 (Sanchez-Caballero et al., 2016).
How assembly factors function is not known, but they may act
as chaperones that stabilize the subcomplexes and help them to
associate to other subcomplexes in order to build the complete
enzyme (Vogel et al., 2007b; Andrews et al., 2013). The fact
that crystal structures of the assembly factors are not available
precludes our understanding of the mechanistic basis of these
proteins at the molecular level (Guarani et al., 2014). These
assembly chaperones may have additional functions besides their
requirement for CI assembly, in line with the evidence that
mitochondria are more than energy producers and are involved
with various (sub)cellular processes that ultimately regulate
mitochondrial metabolic activity (Vogel et al., 2007b).
The Mitochondrial Complex I Assembly
(MCIA) Complex
Most currently identified CI assembly factors are involved in
early assembly and more specifically in the incorporation of
the hydrophobic membrane subunits. The CI assembly factors
NDUFAF1, ACAD9, ECSIT, TMEM126B, and TIMMDC1 form
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the MCIA complex (Heide et al., 2012), which was first identified
in rat heart mitochondria and then in human osteosarcoma
143B cells by complexome profiling (Heide et al., 2012). The
MCIA complex seems to associate with the 370-kDa subcomplex
intermediate, consisting of subunits of the membrane P-proximal
submodule (Figure 1; Lazarou et al., 2007; Andrews et al., 2013).
NDUFAF1
NDUFAF1 (NADH dehydrogenase [ubiquinone] 1 alpha
subcomplex assembly factor 1) is a mitochondrial protein
comprising 327 amino acids including a predicted 24 residue
N-terminal MTS (Figure 2A). NDUFAF1 interacts with nuclear-
and mitochondrial-encoded CI subunits (Supplementary Table
1; Dunning et al., 2007). siRNA-mediated knockdown of
NDUFAF1 results in decreased CI activity and levels, while
overexpression of NDUFAF1 leads to an increase in the CI
expression (Vogel et al., 2005). Based on these results, NDUFAF1
has been proposed to be a chaperone transiently interacting with
CI intermediates (Kuffner et al., 1998; Vogel et al., 2007b) but
the mechanistic details are still elusive.
NDUFAF1 has been identified as the human homolog of
N. crassa CI intermediate-associated protein 30 (CIA30) and is
moderately conserved among species, sharing 28% identity and
exhibiting the highest homology in the C-terminal region of the
protein (Vogel et al., 2005; Figure 2, Supplementary Figure 1).
Interestingly, using structural profile-based homology searches,
the C-terminal region of NDUFAF1 shows a high similarity to
Galactose-binding domain-like proteins, in particular to the non-
catalytic carbohydrate bindingmodule family 11 (CBM11; Viegas
et al., 2008; Figure 2, Supplementary Figure 1). These modules
fold as a β-sandwich structure with a high degree of similarity
between different family members despite an often low level
of sequence similarity. They usually exist within large enzymes,
being involved in recognizing the appropriate glucans for the
catalytic domain and in localizing those domains onto the surface
of the polysaccharide substrates (Elurbe and Huynen, 2016).
The N-terminal region of NDUFAF1 appears to contain a
putative RNA recognition motif (RRM; Figure 2, Supplementary
Figure 1; Marchler-Bauer et al., 2015). The RRM superfamily,
also known as RBD (RNA binding domain) or RNP
(ribonucleoprotein domain), is a highly abundant domain
in eukaryotes and is found in proteins involved in post-
transcriptional gene expression processes including mRNA
and rRNA processing, RNA export, and RNA stability. This
domain is generally 90 amino acids in length with a tertiary
structure consisting of a four-stranded β-sheet packed against
two α-helices. RRM usually interacts with single-stranded
RNA, but is also known to interact with single-stranded DNA
and proteins. RRM binds to a variable number of nucleotides,
ranging from two to eight (Dreyfuss et al., 1988). In NDUFAF1
this domain is predicted to be highly disordered and to be
involved in protein-protein interactions (Figure 2B). NDUFAF1
FIGURE 2 | NDUFAF1 protein domain organization. (A) Human NDUFAF1 predicted domain organization. MTS: mitochondrial signal peptide (residues 1−24).
RRM: predicted RNA recognition motif (residues 14−101) based on a BLAST conservation domain alignment [(Marchler-Bauer et al., 2015); superfamily member
cl17169, Pssm-ID:277499, E-value = 5.72e-04]. The C-terminal half of the protein belongs to the CIA30 family domain [(residues 125−298); superfamily member
cl21728, Pssm-ID:272148, E-value = 6.40e-55], which is predicted to include a carbohydrate-binding module (CMB11) based on InterPro server (ID:IPR005087;
Mitchell et al., 2015). (B) Prediction of disorder tendency of the full-length NDUFAF1 with PSIPRED server (Buchan et al., 2013). High-confidence protein binding sites
are shown in orange lines.
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also contains putative phosphorylation sites such as Ser18
located in the leader sequence and Ser199 located in the central
region (Supplementary Figure 1, residues highlighted in pink;
Janssen et al., 2002). Interestingly, a cAMP-dependent protein
kinase phosphorylation site, located on the 18 kDa subunit of CI,
has been shown to be involved in the activation of the complex
(Janssen et al., 2002).
ECSIT
ECSIT (Evolutionarily conserved signaling intermediate in Toll
pathway) is an adapter protein of 431 amino acids (Kopp et al.,
1999). There are 4 predicted isoforms but only isoforms 1 and 2
have been detected at protein level (Kopp et al., 1999; Xiao et al.,
2003). Although ECSIT was initially identified as a cytoplasmic
and nuclear signaling protein (Kopp et al., 1999; Xiao et al., 2003)
an N-terminal MTS (first 48 amino acids) can direct ECSIT to
mitochondria (Vogel et al., 2007a; Figure 3A).
The N-terminal region of ECSIT (spanning from residues 90
to 266 approximately) seems to be highly ordered (Figure 3B)
and to contain pentatricopeptide repeats (PPR; Supplementary
Figure 2). PPRs are 35-residue repeat motifs that form two
anti-parallel α-helices organized into tandem repeats, typically
binding single-stranded RNA in a sequence-specific andmodular
manner. They were first identified in plant organelles but an
important role in mammalian mitochondrial gene regulation
is now emerging (Rackham and Filipovska, 2012). PPRs are
involved inmany aspects of RNAmetabolism such asmaturation,
translation and stabilizing organelle transcripts. Interestingly,
PPR domain proteins (PTCDs) are predicted to be involved in
the assembly of ETC complexes (Lightowlers and Chrzanowska-
Lightowlers, 2008). Taken together, although no RNA binding
for ECSIT nor NDUFAF1 has been reported, the fact that they
both may contain an RNA binding domain suggests that the
MCIA complex could also be involved in complex biogenesis
by regulating the RNA processing of mitochondrial-encoded
CI subunits (Rackham and Filipovska, 2012; Lightowlers and
Chrzanowska-Lightowlers, 2013; Olahova et al., 2015).
The C-terminal domain of ECSIT shows a higher intrinsic
disorder degree (Figure 3B) and only occurs in metazoa,
indicating that ECSIT itself is also limited to this taxon, i.e.,
the filozoa (Elurbe and Huynen, 2016). Fold recognition
suggests that this domain may be distantly homologous to the
FIGURE 3 | ECSIT protein domain organization. (A) Human ECSIT canonical isoform 1 and isoform 2 predicted domain organization, respectively. MTS:
mitochondrial signal peptide (residues 1−48). PPR: pentatricopeptide repeat motif (central residues 90–266) based on a BLAST conservation domain alignment
[Pssm-ID:276811, Threshold Bit Score = 35.6508 (Marchler-Bauer et al., 2015)]. The C-terminal part seems to fold like a pleckstrin homology (PH) domain (residues
275–380) based on the structure-based homology model server Phyre2 (Kelley et al., 2015). (B) Prediction of disorder tendency of the full-length ECSIT with PSIPRED
server (Buchan et al., 2013). High-confidence protein binding sites are shown in orange lines.
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pleckstrin homology (PH) domain (Kelley et al., 2015). Despite
minimal sequence homology, the three-dimensional structure
is remarkably conserved among PH domains, with minimal
secondary structure elements consisting of seven β-strands
and one C-terminal α-helix (Rebecchi and Scarlata, 1998). The
number and variety of host proteins with PH motifs is large but
most of them can be grouped by function into a few classes:
Ser/Thr protein kinases, Tyr protein kinases, small G-protein
regulators, endocytic GTPases, adaptors, phosphoinositide
metabolizing enzymes, and cytoskeletal associated proteins
(Rebecchi and Scarlata, 1998). Many of them contain a catalytic
domain (e.g., kinase) and other adaptor domains (e.g., SH2 or
SH3) and they are often the targets for protein kinases (Rebecchi
and Scarlata, 1998). Notably, ECSIT isoform 2 lacks this domain
and seems to be involved in the BMP signaling pathway as a
SMAD cofactor, required for normal embryonic development
(Xiao et al., 2003).
ECSIT interacts with a ubiquitin ligase called TRAF6 (tumor
necrosis factor receptor–associated factor 6) and it is involved
in phosphorylation and activation of the nuclear factor NF-ÎB
pathway in innate immunity (Kopp et al., 1999). Ubiquitination
of ECSIT at residue K372 is critical for NF-ÎB binding
activity and its translocation to the nucleus (Wi et al., 2014).
Experimental evidence shows that the N-terminal region of
ECSIT comprising residues 200–260 co-purifies with TRAF6 (Wi
et al., 2014) suggesting that the ECSIT PPR domain might be
involved in TRAF6-specific binding (Figure 3B). The C-terminal
region of ECSIT (residues 260−431) specifically binds to the
TGF-beta-activated kinase 1 (TAK1; Wi et al., 2014), which
could indicate that the PH domain plays a role in the ECSIT-
TAK1 binding to induce the activation of NF-ÎB-dependent gene
expression (Supplementary Figure 2).
Mitochondrial ECSIT participates in CI assembly
(Supplementary Table 2; Vogel et al., 2007a; Nouws et al.,
2010; West et al., 2011). The knockdown of ECSIT in human
cells reduces the levels of NDUFAF1 and results in impaired
CI assembly and activity (Vogel et al., 2007a). In fact, the
mitochondrial isoform of ECSIT was found in 500–600-kDa
and 830-kDa assembly intermediates of CI and associated with
NDUFAF1 (Vogel et al., 2007a). Furthermore, knockdown of
ECSIT in cells results in disturbed mitochondrial function,
supporting a role for ECSIT in linking the assembly of oxidative
phosphorylation complexes with the inflammatory response
(Vogel et al., 2007a).
ACAD9
Acyl-CoA dehydrogenase 9 (ACAD9) is a 621 amino acid protein
with an N-terminal MTS, three Acyl-CoA dehydrogenase
domains, two conserved ACAD motifs and a potential
N-glycosylation site (Figure 4A, Supplementary Figure 3).
ACAD9 undergoes a mitochondrial processing, resulting in
the cleavage of the first 37 amino acids from the precursor
protein and leaving residue A38 as the N-terminal amino acid
of the mature form of the enzyme (Figure 4). The ACAD family
comprises mitochondrial flavoenzymes that catalyze the initial
rate-limiting step of the fatty acid β-oxidation, which is one of
the main energy-producing metabolic pathways in eukaryotes.
While different dehydrogenases target fatty acids of varying
chain length, all ACADs are mechanistically similar and use
FAD as a required co-factor in addition to the presence of
an active site glutamate in order for the enzyme to function.
ACAD9 is very similar to its ancestor, the very long-chain
acyl-CoA dehydrogenase (VLCAD), sharing 47% sequence
identity and 67% similarity (Nouws et al., 2010). ACAD9 was
originally annotated in vertebrates as a result from VLCAD gene
duplication. However, it is has also been found in non-vertebrate
metazoa (Elurbe and Huynen, 2016). The amino acid sequence
of ACAD9 contains the two conserved dehydrogenase signatures
(Supplementary Figure 3) and an important active site residue
(E426; Figure 4A). These features confer some residual acyl
dehydrogenase activity, suggesting that the enzymatic activity
is a rudiment of the VLCAD gene duplication event (Nouws
et al., 2014). However, unlike VLCAD, ACAD9 seems critical for
oxidative phosphorylation (Nouws et al., 2014) and plays a key
role as a CI assembly factor, as shown by different approaches
(Nouws et al., 2010). Indeed, it binds ECSIT and NDUFAF1
(Supplementary Table 3) and mutations on ACAD9 cause
CI deficiencies (Table 2; Nouws et al., 2014). Knockdown of
ACAD9, NDUFAF1, or ECSIT in cultured cells determines the
decrease of all three proteins and of CI holo-complex as well
(Gerards et al., 2011).
A homology model of the structure of an ACAD9 dimer
based on the VLCAD crystal structure is shown in Figure 4B
(Nouws et al., 2010). Unlike other ACADs, human VLCAD,
and ACAD9 contain an extension of the C-terminus that has
been suggested to be involved in intra-mitochondrial membrane
binding (Swigonova et al., 2009). The homodimer model further
indicates that sequence differences in ACAD9 are associated
with two solvent exposed 35 amino acid-long α-helices, which
might represent a new interaction domain important for its
acquired role in respiratory complex assembly in vertebrates
(Supplementary Table 3, Figure 4C; Nouws et al., 2010; Scheﬄer,
2010; Mick et al., 2012). Interestingly, this region is predicted to
be a high-confidence protein binding site (Buchan et al., 2013;
Figure 4B). Furthermore, although the role of the FAD cofactor
in CI assembly is unclear, it may function as a chemical chaperone
and improve specific ACAD9 folding (Nouws et al., 2014).
TMEM126B
Transmembrane protein 126B (TMEM126B) is an integral
component of the inner mitochondrial membrane and comprises
230 residues folded in 4 transmembrane α-helices (Heide et al.,
2012). TMEM126B is found exclusively in mammals and likely
resulted from a segmental duplication of TMEM126A, an
inner mitochondrial membrane protein of unknown function
(Elurbe and Huynen, 2016). Although the molecular function
of TMEM126B has not been clarified yet, it has been recently
discovered that it is required for the CI assembly (Supplementary
Table 4; Heide et al., 2012). One of the critical functions of this
membrane protein might be the recruitment of the hydrophilic
MCIA components to constitute a functional MCIA complex
(Vartak et al., 2014). Indeed, NDUFAF1, ECSIT, and ACAD9 are
not recruited to the membrane in case of lack of TMEM126B,
leading to an MCIA complex misassembly (Vartak et al., 2014).
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FIGURE 4 | ACAD9 protein domain organization. (A) Human ACAD9 domain organization. MTS: mitochondrial signal peptide (residues 1–37). It contains three
Acyl-CoA dehydrogenase/oxidase domains based on InterPro server (Mitchell et al., 2015): N-terminal (residues 65–175, ID:IPR013786); central (residues 177−277,
(Continued)
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FIGURE 4 | Continued
ID:IPR006091); and a C-terminal split into two subdomains (C.1. residues 290–440 and C.2. 507–580, ID:IPR009075). Acyl-dehydrogenase catalytic residue E426 is
shown in red. (B) Prediction of disorder tendency of the full-length ACAD9 with PSIPRED server (Buchan et al., 2013). High-confidence protein binding sites are
shown in orange lines. (C) Multiple alignment of ACAD9 and VLCAD (highlighted in pink) orthologues around ACAD9 residues 383 to 561, based on CLUSTALX
(Larkin et al., 2007) and edited with BioEdit (Hall, 2011). This regions shows the highest sequence variability between ACAD9 and VLCAD homologs and is predicted
to correlate with the folding of an external 35 residue helix (shown in gray) that seems to be absent in the VLCAD crystal structure (PDB code 2UXW, McAndrew et al.,
2008) and which might represent a specific interaction domain site unique for ACAD9. Residue numbering according to human ACAD9 sequence. h, human; m,
mouse; x, African frog; d, zebrafish.
TABLE 2 | Currently identified pathological mutations in CI assembly factors causing CID.
Assembly factors UniProt entries Annotated mutations Disease phenotypes References
NDUFAF1 Q9Y375 H92R, T207P, K253R, R211C, G245R LS, L, HC Dunning et al., 2007; Fassone et al., 2011; Dewulf
et al., 2016
NDUFAF2 Q8N183 M1L, W3STOP, Y38STOP, R45STOP,
W74STOP, I35SfsX17a, A73GfsX5a
LS, L Ogilvie et al., 2005; Barghuti et al., 2008; Hoefs
et al., 2009; Janssen et al., 2009; Calvo et al., 2010;
Herzer et al., 2010; Ghaloul-Gonzalez et al., 2016
NDUFAF3 Q9BU61 M1T, G77R, R122P FLA Saada et al., 2009
NDUFAF4 Q9P032 L65P LS, L Saada et al., 2009
NDUFAF5 Q5TEU4 L159F, L229P LS Sugiana et al., 2008; Gerards et al., 2010
NDUFAF6 Q330K2 Q99R LS, L Pagliarini et al., 2008
NDUFAF7 Q7L592 n.d. n.d.
FOXRED1 Q96CU9 Q232STOP, R352W, V421M, N430S LS, L Calvo et al., 2010; Fassone et al., 2011; Zurita
Rendón et al., 2014
NUBPL Q8TB37 G56R, D105Y, L193F, E223AfsX4a,
240-kb deletion (exons 1–4); 137-kb
duplication (exon 7)
LS, L Calvo et al., 2012; Tucker et al., 2012; Kevelam
et al., 2013
TMEM126B Q8IUX1 G212V, N134IfsX2a CID Alston et al., 2016
ACAD9 Q9H845 F44I, E63STOP, F120SfsX9a, R127Q,
A170V, G172R, S268F, T243R,
R266Q/W, L314P, A326P, F339V,
E413K, R414S, R417C, R433Q,
R469W, R518C, R532W/Q, V546L,
L558PfsX45a, H563A
LS, L, HC Scholte et al., 1995; Haack et al., 2010; Nouws
et al., 2010; Gerards et al., 2011; Collet et al., 2016;
Dewulf et al., 2016; Leslie et al., 2016; Pronicka
et al., 2016
ECSIT Q9BQ95 n.d. n.d.
TIMMDC1 Q9NPL8 n.d. n.d.
LS, Leigh syndrome; L, leukodystrophy; HC, hypertrophic cardiomyopathy; FLA, fatal lactic acidosis, encephalopathy; CID, complex I deficiencies; n.d., not determined or not (yet)
associated with disease.
afsX = frameshift.
Furthermore, depletion of TMEM126B leads to accumulation
of the Q module-ND1 intermediate (Guarani et al., 2014) and
severely impairs mitochondrial respiration (Heide et al., 2012).
TIMMDC1
The translocase of inner mitochondrial membrane domain-
containing 1 (TIMMDC1) protein contains 285 residues
embedded in four transmembrane α-helices. It belongs
to the TIM17-TIM22-TIM23 (translocases of the inner
mitochondrial membrane) domain family, which are membrane-
embedded multi-protein complexes that mediate the transport
of nuclear-encoded proteins across and into inner mitochondrial
membranes (Kurz et al., 1999; Chacinska et al., 2005). Recent
data show that the transmembrane protein TIMMDC1 is also
physically associated with the MCIA complex and functions
in CI assembly (Supplementary Table 5; Guarani et al.,
2014). Depletion of TIMMDC1 in tissue culture cells leads
to accumulation of CI subcomplexes similar to MCIA factor
depletion effects, resulting in impaired CI activity and cellular
respiration and a decreased stability of several CI subunits
(Guarani et al., 2014).
The Molecular Assembly of the MCIA
Complex
Overall, the available data show that depletion of the MCIA
factors NDUFAF1, ECSIT, or ACAD9 leads to the accumulation
of the 370-kDa assembly intermediate from the CI membrane
arm, which contains mtDNA-encoded subunits with about
20 transmembrane α-helices (Andrews et al., 2013). How
the MCIA factors function is not known yet, but they may
stabilize this subcomplex and promote its incorporation to the
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other subcomplexes to build up the complete holo-enzyme.
However, the MCIA complex could also have a more general
function, regulating CI assembly at the translation level by the
induction and stabilization of the transcripts of mtDNA-encoded
subunits when required (Supplementary Tables 2–5). The fact
that the sequential assembly pathway of MCIA factors is still
incomplete suggests that additional extrinsic and/or intrinsic
assembly factors remain to be identified (Table 1; Andrews et al.,
2013).
The homology model of ACAD9 dimer provides initial
insights into the molecular assembly of the MCIA complex
(Figure 5). In a first step, the newly proposed interaction domain
of ACAD9 homodimer could bind to ECSIT and NDUFAF1,
respectively, forming a tetrameric complex that would then
interact with the membrane assembly factor TMEM126B to
anchor the MCIA complex onto the membrane (Nouws et al.,
2010). Indeed, it has been suggested that TMEM126B would
insert hydrophobic proteins into the 370-kDa subcomplex
to subsequently associate with the 315-kDa subassembly and
to finally constitute a subcomplex of 550 kDa (Andrews
et al., 2013). Furthermore, TIMMDC1 could be involved in
the transfer of newly imported nuclear-encoded subunits and
MCIA factors as well, similarly to the other family member
TIM21 in CIV assembly (Mick et al., 2012). TIMMDC1
would then engage with assembly factors after import and,
as it has been recently speculated, it would also function
as a membrane anchor to assemble additional components
of the MCIA complex, together with both the Q module
components and the major membrane arm, and to organize
intermediates into a productive assembly pathway (Guarani
et al., 2014). During the final stages of CI assembly, these
factors would dissociate, since these proteins are not found
associated with the mature holo-enzyme (Mckenzie and Ryan,
2010).
Nonetheless, considering that protein disorder prediction
algorithms are not 100% accurate, especially for transmembrane
topology prediction (Buchan et al., 2013), experimental data
are essential for a complete understanding of the MCIA
complex assembly and the underlying molecular mechanisms
of the CI assembly process at the structural level. The
development of reconstituted systems at high resolution by
X-ray crystallography or electron microscopy will thus enable to
unravel the protein complex organization down to the atomic
detail.
FIGURE 5 | Proposed model of the molecular assembly of the MCIA complex and its role in the assembly of the CI. Complete view of the assembly
pathway indicating the steps where MCIA assembly factors are involved (see text for details). Representation of mammalian mitochondrial CI model is based on the
bovine heart cryo-EM structure [(Vinothkumar et al., 2014); PDB 4UQ8]; ACAD9 on the homology model proposed by (Nouws et al., 2010); NDUFAF1, ECSIT,
TIMMDC1, and TMEM126B on putative homology folding. The matrix-hydrophilic functional modules are colored in green (N) and orange (Q), respectively.
Membrane-embedded modules, in blue (Pp, Pump proximal), and in salmon (Pd, Pump distal). CI subunits with reported interactions with MCIA factors are shown in
red. MIM, mitochondrial inner membrane.
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DEFECTS IN COMPLEX I ASSEMBLY
RESULT IN NEURODEGENERATIVE
DISEASES
As described earlier, CI acts as metabolism hub essential in
cellular energy production, but it is also the major source of
ROS production. Redox signals can mediate through cysteine
oxidation, namely S-oxidation, S-glutathionylation, and S-
nitrosylation, which have been shown to also regulate CI
activity (Bak andWeerapana, 2015; Mailloux, 2015). Hence, even
subtle defects in CI assembly or function are directly linked
to oxidative stress and ultimately to mitochondrial dysfunction
and disease. When ROS production overwhelms the endogenous
antioxidant systems this can lead to oxidative damage in mtDNA,
membranes or proteins, impairing cellular functions such as
ATP and heme synthesis, fatty acid oxidation, or the urea and
tricarboxylic acid cycles. Mitochondrial ROS damage can also
lead to cytochrome-c release to the cytosol by mitochondrial
outer membrane permeabilization and thereby trigger apoptosis
through the activation of the caspase cascade (Jeong and Seol,
2008). Neuronal cells are particularly susceptible to ROS-induced
damage because they mainly rely on oxidative metabolism for
ATP generation, in contrast to glial cells, which are highly
glycolytic (Belanger et al., 2011). However, there are metabolic
interactions from astrocytes to neurons that appear to play an
important role in the control of neuronal activity and excitability
(Belanger et al., 2011).
Mitochondrial integrity also declines as a consequence
of aging. Interestingly, some of the functional impairments
seem to be correlated with increasing oxidative stress derived
from defects in the OXPHOS system. Furthermore, age-
related neurodegenerative diseases (NDs) may exacerbate the
oxidative damage. Indeed, mitochondrial dysfunction represents
a common pathogenic mechanism in NDs like Alzheimer’s
disease (AD), Parkinson’s disease (PD), amyotrophic lateral
sclerosis, Huntington’s disease, and prion diseases (Beal, 2002;
Lin and Beal, 2006; Tillement et al., 2011; Federico et al., 2012;
Schapira, 2012; Butterfield et al., 2016). In particular, CI activity
is reduced with aging, as demonstrated in primate brains and
in long-lived mice models (Bowling et al., 1993; Miwa et al.,
2014). Typically, genetic defects in CI and its assembly factors
account for a heterogeneous group of fatal disorders collectively
known as complex I deficiencies (CID). However, recent clinical
and experimental studies also indicate a possible link between
CI dysfunction and the pathogenesis of AD or PD, which have
accelerated the interest toward investigations into CI biology
as a promising therapeutic target for NDs (Eckert et al., 2010;
Winklhofer and Haass, 2010).
Neurodegeneration Associated with
Complex I Deficiencies
CID is the most prevalent genetic defect in mitochondrial
energy metabolism, accounting for approximately a third
of the OXPHOS disorder cases (Kirby et al., 1999). CID is
characterized by marked genetic, tissue, and organ specific
heterogeneity with often overlapping clinical phenotypes. The
majority of the affected patients also presents Leigh syndrome
(LS): a fatal, incurable, rapidly progressive neurodegenerative
disorder typically occurring within the first weeks/months
after birth and with an incidence of at least 1 case out of
40,000 live births (Darin et al., 2001). Neuropathologically, LS
features bilateral symmetrical necrotic lesions characterized
by spongiosis, neuronal loss, astrocytosis, and capillary
proliferation; clinical signs and symptoms include muscular
hypotonia, developmental delay, abnormal eye movements,
respiratory abnormality, seizures, and ataxia (Leigh, 1951;
Rahman et al., 1996). Additional CID clinical phenotypes have
been associated with other childhood ND, including Leigh-
like syndrome, leukoencephalopathy, MELAS (mitochondrial
encephalomyopathy, lactic acidosis and stroke-like episodes),
and NARP (neuropathy, ataxia and retinitis pigmentosa)
syndromes (Fassone and Rahman, 2012; Koopman et al., 2016).
Mutations in six mtDNA-encoded (ND1 to 6) and thirteen
nuclear-encoded (NDUFS1 to 8; NDUFV1; NDUFA1, 2, 9, 10,
and 12) CI subunits have been correlated to LS (Rodenburg,
2016). Early investigations on CID patient-derived fibroblasts
showed partial or incomplete CI assembly and diminished
catalytic activity (Verkaart et al., 2007a), which was inversely
correlated with ROS production in mitochondria-enriched
fractions (Koopman et al., 2007; Verkaart et al., 2007b).
In addition, CID patient fibroblasts showed a significantly
depolarized mitochondrial membrane, which in turn caused a
dramatic effect on ATP production and protein transport across
mitochondrial membranes (Komen et al., 2007; Distelmaier et al.,
2009a,b). Finally, aberrations in CI activity have an impact
in the calcium homeostasis, a crucial stimulus for activating
ATP production via OXPHOS, as observed in CID derived
cells (Willems et al., 2008). Nevertheless, while much progress
has been made in elucidating the structure of mammalian
CI, the molecular mechanisms underlying CID are still poorly
understood.
Moreover, clinical studies have reported that only about 33%
of the CID cases are associated with specific genetic defects
in the 44 CI subunits (Calvo et al., 2010), revealing that
assembly factors may account for the remaining CID cases
(Nouws et al., 2012). Interestingly, the first evidence of the role
of assembly factors in CID comes from the identification of
pathological mutations in genes encoding for MCIA components
and other CI assembly factors, most of them linked to CID
but with an additional broad spectrum of disease phenotypes,
such as LS, leukodystrophy, MELAS and NARP syndromes
(Table 2; Nouws et al., 2012; Rodenburg, 2016; Wu et al.,
2016). Along this line, several ACAD9 mutations are associated
to CID (Haack et al., 2010; Rodenburg, 2016) and indeed,
stabilization of ACAD9 might represent a therapeutic approach
for treating CID, as shown by a riboflavin treatment (the
central component of FAD cofactors) where CI activity increased
and clinical conditions of ACAD9-defective patients improved
(Gerards et al., 2011). Some other MCIA factors may display a
pleiotropic role in cells, such as ECSIT, which was identified as
an inter-pathway protein node interacting with Aβ-producing
enzymes (Soler-Lopez et al., 2011), suggesting a link between
CI assembly/stability and AD pathogenesis. Upon inflammation
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or Aβ insult, ECSIT may expand the signaling of the immune
response to the inner-mitochondrial level, e.g., by stabilizing CI
to ensure mitochondrial physiology, or induce apoptosis when
repair failure (Soler-Lopez et al., 2012). Recently, two biallelic
mutations have been identified in TMEM126B, which cause CID
with a broad disease phenotype. Interestingly, patient-derived
cell lines show markedly CI assembly defects (like accumulation
of intermediates) and decreased levels of the remaining MCIA
components: ECSIT, ACAD9, and NDUFAF1 (Alston et al.,
2016).
Notably, recent investigations have revealed that around
40% of CID cases are not associated with mutations in CI
subunit or assembly factor encoding genes, suggesting that other
yet unknown factors may affect the proper function of the
ETC (Taylor et al., 2014). These findings have prompted the
interest toward the identification of novel assembly factors in
order to provide a genetic explanation and potential therapeutic
strategies for those CID cases not directly linked to CI subunit
mutations. To achieve this goal, genome-wide sequencing,
proteomic and structural approaches will be highly relevant in
the identification and characterization of CID-associated genes
whose physiological roles are still undetermined.
Complex I Dysfunction and Parkinson’s
Disease
CI dysfunction also seems to be critical in PD pathogenesis,
correlated with the degeneration of dopaminergic neurons in
the substantia nigra pars compacta (Schapira et al., 1990; David
et al., 2005; Keeney et al., 2006; Gatt et al., 2016). One of the PD
pathological hallmarks is the presence of intracellular inclusions
called Lewy bodies that consist of aggregates of the presynaptic
protein α-synuclein (Dawson and Dawson, 2003). Besides α-
synuclein, several proteins have also been associated with PD,
some of which (e.g., DJ-1, PINK1, Parkin, HTRA2) localize in
the mitochondria and gain toxic functions due to mutations that
may lead to mitochondrial dysfunction (Federico et al., 2012). In
fact, CI defects and increased oxidative damage are consistent
features of both sporadic (idiopathic) and familial (genetic) PD
forms. Decrease of CI activity has been reported in the substantia
nigra and in the cortex of PD patients (Haelterman et al., 2014).
Early experiments studying CI induced inhibition by
agrochemicals, such as rotenone or 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), showed a correlation with PD
symptoms like the formation of α-synuclein containing
inclusions, bioenergetics defects and ROS overproduction (Liang
et al., 2007; Sherer et al., 2007). Although it is plausible that
a chronic exposure to CI inhibitors might contribute to the
development of sporadic PD, it is unlikely that toxin exposure
accounts for CI defects in the general population. An alternative
hypothesis proposes that inherited or somatic mutations in
mtDNA might account for CI defects triggering oxidative stress
and PD, experimentally supported by PD cytoplasmic hybrid
(i.e., cybrid) cell lines showing higher ROS levels (Swerdlow et al.,
1996; Gu et al., 1998). Different studies have reported somatic
mutations in ND4 and ND5 CI subunits in PD patients (Simon
et al., 2004; Parker and Parks, 2005). Furthermore, α-synuclein
contains an MTS that enables an eventual translocation to the
inner mitochondrial membrane (Martin et al., 2006). How
mitochondrial localization of α-synuclein affects mitochondrial
function in human brain has not been addressed in detail,
although independent observations propose a role for α-
synuclein in maintaining the OXPHOS physiological functions
(Ellis et al., 2005; Devi et al., 2008). In transgenic (tg) mice,
over-expression of α-synuclein impairs mitochondrial function,
increases oxidative stress and enhances the substantia nigra
pathology induced by MPTP (Song et al., 2004). Interestingly,
in vivo data using human fetal dopaminergic primary neuronal
cells and PD brain-derived tissues (striatum and substantia
nigra) have shown a progressive accumulation of α-synuclein
in the mitochondria resulting in impaired CI functioning and
increased oxidative stress. Remarkably, α-synuclein has been
found in direct association with the ∼600-kDa subcomplex and
the holo-CI in mitochondria derived from PD patients (Devi
et al., 2008). These results suggest that α-synuclein accumulation
in the mitochondrial matrix may also affect the proper assembly
of CI and lead to mitochondrial dysfunction. Other studies have
shown that some core (ND4, ND5, NDUFS1, NDUFS2, and
NDUFV1) and accessory (NDUFB5, NDUFB6, and NDUFB7)
subunits are oxidatively damaged in PD brains, resulting in CI
misassembling and functional impairment (Keeney et al., 2006).
Overall, these findings support the assumption that CI
misassembly may play a role in PD onset and progression.
However, the molecular mechanisms contributing to the
instability of CI assembly, loss of bioenergetic functions and
oxidative stress are yet unclear. It is tempting to speculate that
abnormal α-synuclein accumulation inmitochondria, mutations,
or polymorphisms in PD-associated mitochondrial genes may
lead to defects in the CI assembly process, which eventually plays
a central role in PD pathology.
Complex I Dysfunction and Alzheimer’s
Disease
AD is the most prevalent form of ND, characterized by
a progressive memory loss and impairment of cognitive
abilities (Duyckaerts et al., 2009; Hyman et al., 2012). At the
neuropathologic level, it reveals the presence of amyloid plaques
and neurofibrillary tangles (NFT) as the final result of misfolding
and aggregation of amyloid-β (Aβ) and tau proteins. Aβ is
the cleavage product of a much larger protein, the Amyloid
Precursor Protein (APP), by α-, β-, and γ-secretases (Selkoe,
2001). Although different Aβ truncated species can be generated
during the cleavage process (Willem et al., 2015), Aβ1−42
(i.e., the 42-amino acid form of Aβ) is the most neurotoxic
peptide and represents the majority of Aβ deposits in AD brain
(Welander et al., 2009). Aβ deposition leads to the formation
of plaques in neuronal (neurites and synaptic terminals) and
glial (astrocytes and microglia) cells. NFTs are intracellular
aggregates of abnormal hyper-phosphorylated tau that form
cytoplasmic fibrils (Braak et al., 1994). While the neurotoxicity
of Aβ and tau misfolding, aggregation and spreading have
been deeply investigated, much less is known about the early
molecular events underlying AD pathogenesis. Intraneuronal Aβ
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accumulation has emerged as one of the main causative effects
of synaptic damage and cognitive decline in AD (LaFerla et al.,
2007). According to the AD mitochondrial hypothesis, defects
in mitochondrial metabolism and particularly in the ETC may
play a role during the early stage of AD pathogenesis (Valla
et al., 2001). Aβ has been detected in mitochondria from both
tg mice and murine cell lines expressing human mutant APP,
displaying increased ROS production, decreased cytochrome
oxidase activity, morphological mitochondrial alteration, and
apoptosis (Manczak et al., 2006; Cha et al., 2012). Furthermore,
Aβ has also been associated with mitochondria from AD
patients, showing mitochondrial fragmentation in various brain
regions (Reddy et al., 2010). As extensively reviewed, Aβ
accumulation in the mitochondria leads to different mitotoxic
events, such as permeabilization of membranes, reduction of
respiratory function, and disturbance of the mitochondrial
calcium homeostasis (Swerdlow et al., 2010; Moreira et al., 2010a;
Tillement et al., 2011). Among these mechanisms, impaired
OXPHOS functions have been frequently observed in AD
patients and in different AD tg mouse and cellular models
(Hroudova et al., 2014).
Clinical investigations have reported impairment of CI activity
and reduced level of its subunits in multiple zones of post mortem
AD brains (Mutisya et al., 1994; Aksenov et al., 1999; Kim et al.,
2000, 2001), as well as in other tissues such as platelets (Cardoso
et al., 2004). A number of proteomic studies on AD tg mouse
models have provided clear evidence of the involvement of Aβ
and tau proteins in CI defects and consequent mitochondrial
dysfunction (David et al., 2005; Rhein et al., 2009; Chou et al.,
2011; Zhang et al., 2015). Interestingly, tg mice overexpressing
the tau P301L mutation (i.e., causing hyperphosphorylated tau
accumulation and NFT) exhibit reduced CI activity and, with
age, impaired mitochondrial respiration and ATP synthesis.
Furthermore, isolated cortical brain cells from this mouse model
display modified lipid peroxidation, increased ROS production
and altered mitochondrial membrane potential after Aβ insults
(David et al., 2005). This finding has led to propose a tau
and Aβ synergistic contribution to mitochondrial pathology
by inhibiting ETC -particularly CI- and inducing ROS-derived
apoptosis. Consistent with this hypothesis, deregulation of CI
and CIV has also been observed in triple-tg AD mice, (co-
expressing AD-linked mutations in presenilin 2, APP, and tau
proteins; Rhein et al., 2009). Importantly, in 8-month old
tg mice (i.e., prior the appearance of the disease symptoms)
deregulation of CI seems to be tau-dependent, whereas that of
CIV is Aβ-dependent. However, with aging and especially in
the presence of both Aβ plaques and NTF, defects on CI and
CIV become more marked resulting in a significant decrease
of respiratory parameters, reduced mitochondrial membrane
potential and increased ROS level, providing further evidence
to a synergistic detrimental effect of Aβ and tau on ETC
(Rhein et al., 2009). Furthermore, in support of the central
role of CI in AD pathogenesis, recent data suggest that CI-
derived ROS contributes to amyloidogenic APP processing
(Leuner et al., 2012; Tamagno et al., 2012; Bobba et al., 2013).
Taken together, Aβ- or tau-mediated CI impairment result
in a vicious cycle inducing electron leakage from the ETC
leading boosting mitochondrial dysfunction and oxidative stress.
Notably, pathological mechanisms underlying AD pathogenesis
share common features with LS and the other CID forms
previously described. A link between CID and AD has been
recently established with the identification of a naturally
occurring mutation, S339G, in the ND4 core subunit of CI
of a premature aging mouse strain, SAMP8 (Imanishi et al.,
2011). SAMP8 mice develop early learning and memory deficits
together with other characteristics similar to those seen in
AD, including ROS overproduction and Aβ plaques with aging
(Morley et al., 2000, 2012). Interestingly, an adjacent human
mutation, R340H, in the ND4 gene also results in CID with
associated LS, Leber hereditary optic neuropathy and late onset
MELAS syndrome, characterized by increased ROS production
and altered CI assembly (Wong et al., 2002; Deschauer
et al., 2003), prompting a new investigative field for the
development of therapeutic approaches targeting mitochondria
for the treatment of AD and CID (Friedland-Leuner et al.,
2014).
PERSPECTIVES IN MITOCHONDRIAL
NEUROBIOLOGY
Emerging evidence suggest a pivotal role of mitochondrial
dysfunction in the pathogenesis of major neurodegenerative
disorders. In particular, CID is the most common OXPHOS
disorder in humans and defects in CI assembly process are
often detected. From a clinical point of view, mitochondrial
biology holds the promise to provide novel insights into the
pathogenesis of several NDs. Different proteomic investigations
on mitochondrial proteins differentially expressed in CID
(Pagliarini et al., 2008; Alston et al., 2016), AD (Sultana
et al., 2011), and PD (Henchcliffe and Beal, 2008) suggest that
proteins involved in CI assembly and functioning might be
novel targets for biomarker identification, disease progression
and ultimately, therapeutic approaches. Several drug discovery
studies are under development to boost mitochondrial health
or tune up the mitochondrial power engine to compensate for
damaged or interrupted neuronal power failure upon neuronal
stress (Moreira et al., 2010b). Novel therapeutic strategies will
thus enable mitochondria to better cope with oxidative stress,
excitotoxicity, and other neuronal stresses, as well as maintain
efficient respiratory function in neurons. However, the drugs
tested in most of the current trials do not target mitochondria
but monitor mitochondrial function as an indicator of indirect
effects of the treatments (Wang et al., 2016). There is increasing
evidence that a fully assembled and stable CI is key in
various pathways. Therefore, a better understanding of the
regulatory mechanisms underlying CI assembly will unveil how
mitochondria malfunction affects metabolic reprogramming and
neuronal integrity. To this end, the molecular characterization
of existing and novel assembly factors emerges as a promising
approach for mitochondria-targeted therapeutics, the so-called
mitochondrial medicine (Weissig et al., 2004), and for specific
discrimination among ND disorders, with CI assembly factors
gaining a new and exciting dimension.
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CONCLUSIONS
Despite the critical importance of CI in energy production
and disease, many aspects of its assembly and activity
are still poorly understood, since they require a stepwise
coordination of different processes and components that
are tightly interconnected. Clinical data have enabled the
identification of CI subunits and assembly factors implicated in
neurodegeneration, but they provide a limited understanding.
Furthermore, other yet unknown factors may be involved in
the proper function of the ETC. In this review, we have
presented the current knowledge of CI structure and its
assembly factors, with a particular focus on neurodegenerative
disorders. Pathological mutations in CI assembly factors seem
to affect the functional integrity of the holo-enzyme, although
they have not been investigated at the molecular level yet.
Therefore, structural studies on such proteins together with in
vivo experiments will help us to elucidate the dynamics of CI
biogenesis and will thus contribute to a better understanding
of the altered mitochondrial pathways involved in neuronal
death. These efforts will provide unique insights and will have
a major contribution in the quest for novel disease-modifying
approaches, where CI assembly factors might play a central
role.
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